Summary
DexCom, Inc. (DXCM) in its 2017 10-K filing, details its position as a leading medical device company focused on continuous glucose monitoring (CGM) systems for individuals with diabetes. The company highlights the development and commercialization of its G4 PLATINUM and G5 Mobile systems, emphasizing the G5 Mobile's "non-adjunctive" indication that allows for reduced fingerstick calibration, a significant advancement for diabetes management. Financially, DexCom reported significant revenue growth, driven by increased sales volume of disposable sensors and durable systems. However, the company also incurred operating losses, reflecting substantial investments in research and development, sales and marketing, and manufacturing capacity expansion. Key strategies include leveraging its technology platform, driving adoption through sales and partnerships, expanding market reach to Type 2 diabetes patients, and securing broad reimbursement coverage, particularly from Medicare. The company is also actively pursuing collaborations for data and insulin delivery integration. Significant risks identified include intense competition, reliance on third-party suppliers, regulatory hurdles and potential delays in product approvals, and the crucial aspect of securing consistent and adequate reimbursement from payors like Medicare and private insurers. The company is also investing in expanding its manufacturing capabilities, including a new facility in Mesa, Arizona, to meet anticipated demand.
Financial Highlights
54 data points| Revenue | $718.50M |
| Cost of Revenue | $226.40M |
| Gross Profit | $492.10M |
| R&D Expenses | $185.40M |
| SG&A Expenses | $349.20M |
| Operating Expenses | $534.60M |
| Operating Income | -$42.50M |
| Interest Expense | $12.80M |
| Net Income | -$50.20M |
| EPS (Basic) | $-0.14 |
| EPS (Diluted) | $-0.14 |
| Shares Outstanding (Basic) | 345.20M |
| Shares Outstanding (Diluted) | 345.20M |
Key Highlights
- 1DexCom is a key player in the Continuous Glucose Monitoring (CGM) market, with its G5 Mobile system offering a "non-adjunctive" indication, reducing the need for frequent fingerstick calibration, a significant user benefit.
- 2The company reported strong revenue growth in 2017, driven by increased sales of disposable sensors and durable systems, indicating growing adoption of its CGM technology.
- 3Despite revenue growth, DexCom continued to experience operating losses, reflecting significant ongoing investments in R&D, sales, marketing, and manufacturing infrastructure.
- 4Strategic priorities include expanding market reach to Type 2 diabetes patients, forming partnerships for data and insulin delivery integration, and advocating for broader reimbursement coverage from payors.
- 5Regulatory approval remains a critical factor, with ongoing efforts to secure clearances for future products and expanded indications, alongside the ongoing reliance on FDA approvals for market access.
- 6The company faces intense competition from established medical device manufacturers and emerging CGM technologies, necessitating continuous innovation and effective market penetration.
- 7Securing and maintaining favorable reimbursement from Medicare and private third-party payors is crucial for widespread adoption and revenue generation, presenting a significant ongoing challenge.